Keyphrases
Chronic Lymphocytic Leukemia
100%
Richter Transformation
100%
Venetoclax
100%
Confidence Interval
50%
Chemoimmunotherapy
50%
Odds Ratio
37%
Complete Response Rate
37%
Cyclophosphamide
25%
Doxorubicin
25%
Rituximab
25%
Prednisone
25%
Treatment Group
25%
Nave
25%
Tumor Protein p53 (TP53)
12%
Hazard Ratio
12%
Survival Estimation
12%
Poor Prognosis
12%
Overall Survival
12%
Neutropenia
12%
Thrombocytopenia
12%
Clinical Characteristics
12%
Progression-free Survival
12%
Patient Demographics
12%
Clinical Trials
12%
Median Progression-free Survival
12%
Overall Response Rate
12%
Infection Rate
12%
Multicenter Retrospective Study
12%
Durable Remission
12%
Combination Regimen
12%
High Response Rate
12%
Difficult-to-treat
12%
Best Overall Response
12%
Bruton Tyrosine Kinase Inhibitor
12%
De Novo Diffuse Large B-cell Lymphoma
12%
Baseline Characteristics
12%
Del17p
12%
Bcl-2 Inhibitor
12%
Agent Efficacy
12%
Medicine and Dentistry
B-Cell Chronic Lymphocytic Leukemia
100%
Richter's Transformation
100%
Venetoclax
100%
Chemoimmunotherapy
50%
Odds Ratio
37%
Cyclophosphamide
25%
Vincristine
25%
Rituximab
25%
Progression Free Survival
25%
Doxorubicin
25%
Treatment Group
25%
Prednisone
25%
Retrospective Study
12%
Hazard Ratio
12%
Survival Estimate
12%
Clinical Trial
12%
Overall Survival
12%
Diffuse Large B-Cell Lymphoma
12%
Neutropenia
12%
Patient Population
12%
Thrombocytopenia
12%
Bruton Tyrosine Kinase Inhibitor
12%
Infection Rate
12%
Pharmacology, Toxicology and Pharmaceutical Science
Chronic Lymphatic Leukemia
100%
Venetoclax
100%
Vincristine
25%
Cyclophosphamide
25%
Doxorubicin
25%
Progression Free Survival
25%
Prednisone
25%
Rituximab
25%
Treatment Group
25%
Retrospective Study
12%
Overall Survival
12%
Clinical Trial
12%
Thrombocytopenia
12%
Neutropenia
12%
Remission
12%
Diffuse Large B Cell Lymphoma
12%
Infection Rate
12%
Bruton Tyrosine Kinase Inhibitor
12%